Loading Events

Upcoming Events › Grant

Events Search and Views Navigation

Event Views Navigation

December 2020

Community Action Grants

December 1

Sponsor: American Association of University Women
Due Date: December 1, 2020
Award: Community Action Grants provide funding to individuals, AAUW branches and AAUW state organizations as well as community-based nonprofits for innovative programs or non-degree research projects that promote education and equity for women and girls. Awards include $2,000-$7,000 for one year grants and $5,000-$10,000 for two year grants

Find out more »

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Award

December 31

Sponsor: International Rett Syndrome Foundation (IRSF)
Due Date: Applications accepted on a rolling basis
Award: Up to $600,000 over two years. Grant awards must be comprised of very specific programs that are focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates.

Find out more »

Rolling Basis: Alzheimer’s Drug Discovery Foundation

December 31

PROPOSALS ACCEPTED ON A ROLLING BASIS
ADDF/NIH
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Conference Funding
Supports scientific conferences that are relevant to our mission with grants up to $10,000.

Find out more »

January 2021

NIH R43/44 and U43/44

January 5, 2021
|Recurring Event (See all)

One event on January 5, 2021 at 12:00 am

One event on April 5, 2021 at 12:00 am

Sponsor: National Institutes of Health
DUE DATES: (same every year)

  • Cycle 1: Jan 5
  • Cycle 2: April 5
  • Cycle 3: September 5

BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR) (R43/R44 – Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.

Find out more »

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

January 10, 2021
|Recurring Event (See all)

One event on January 10, 2021 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 12, 2020, January 10, 2021
Application Due Date: August 11, 2020, February 9, 2021
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »

February 2021

NIH R21, R03

February 16, 2021
|Recurring Event (See all)

One event on February 16, 2021 at 12:00 am

One event on October 16, 2021 at 12:00 am

Sponsor: National Institute of Health 
DUE DATES: 

  • Cycle 3: October 16, 2020 by 5 PM of local organization time
  • Cycle 1: February 16, 2021 by 5 PM of local organization time
  • Cycle 2: June 16, 2021 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

April 2021

NIH R43/44 and U43/44

April 5, 2021
|Recurring Event (See all)

One event on January 5, 2021 at 12:00 am

One event on April 5, 2021 at 12:00 am

Sponsor: National Institutes of Health
DUE DATES: (same every year)

  • Cycle 1: Jan 5
  • Cycle 2: April 5
  • Cycle 3: September 5

BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR) (R43/R44 – Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.

Find out more »

October 2021

NIH R21, R03

October 16, 2021
|Recurring Event (See all)

One event on February 16, 2021 at 12:00 am

One event on October 16, 2021 at 12:00 am

Sponsor: National Institute of Health 
DUE DATES: 

  • Cycle 3: October 16, 2020 by 5 PM of local organization time
  • Cycle 1: February 16, 2021 by 5 PM of local organization time
  • Cycle 2: June 16, 2021 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »
+ Export Events